The importance of pharmacoepidemiology in pregnancy-implications for safety

Expert Opinion on Drug Safety

Volumn 16, Issue 10, 2017, Pages 1181-1190

  Benevent, Justine ^a   Montastruc, Francois ^a   Damase Michel, Christine ^a  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

Author keywords

Electronic database; medication; pharmaco epidemiology; pregnancy; teratogen

Indexed keywords

CHILDHOOD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONGENITAL MALFORMATION; DATA BASE; DISEASE REGISTRY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INFORMATION CENTER; PHARMACOEPIDEMIOLOGY; POPULATION BASED CASE CONTROL STUDY; PREGNANCY; PREGNANT WOMAN; REVIEW; ADVERSE EFFECTS; ANIMAL; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MATERNAL EXPOSURE; METHODOLOGY; PRENATAL EXPOSURE; PROCEDURES;

PRESCRIPTION DRUG;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MATERNAL EXPOSURE; PHARMACOEPIDEMIOLOGY; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRESCRIPTION DRUGS; RESEARCH DESIGN;

EID: 85029513951     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2017.1363177     Document Type: Review

References (59)

1. Stadler J., [Developmental and reproductive toxicology:interest and interpretation]. Therapie. févr. 2014;69(1):25–30.
2. Pregnancy:Clinical Trials [Internet]. [cité mai 2017 24]. Disponible sur:https://www.nichd.nih.gov/health/topics/pregnancy/clinicaltrials/Pages/default.aspx
3. European Medicines Agency - Pharmacovigilance - Good pharmacovigilance practices [Internet]. [cité mai 2017 24]. Disponible sur:http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp
4. Damase-Michel C, Pichereau J, Pathak A, et al. Perception of teratogenic and foetotoxic risk by health professionals:a survey in Midi-Pyrenees area. Pharm Pract. 2008 janv;6(1):15–19.
5. Herd P, Higgins J, Sicinski K, et al. The implications of unintended pregnancies for mental health in later life. Am J Public Health. 2016 mars;106(3):421–429.
6. Moreau C, Bohet A., Frequency and correlates of unintended pregnancy risk perceptions. Contraception. Août 2016;94(2):152–159.
7. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet Lond Engl. 23 Oct. 1982;2(8304):937.
8. Damase-Michel C, Vié C, Lacroix I, et al. Drug counselling in pregnancy:an opinion survey of French community pharmacists. Pharmacoepidemiol Drug Saf. Oct 2004;13(10):711–715.
9. Damase-Michel C, Lapeyre-Mestre M, Moly C, et al. [Drug use during pregnancy:survey in 250 women consulting at a university hospital center]. J Gynecol Obstet Biol Reprod (Paris). févr. 2000;29(1):77–85.
10. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, et al. Prescription of drugs during pregnancy in France. Lancet Lond Engl. 18 nov. 2000;356(9243):1735–1736.
11. ENCePP Home Page [Internet]. [cité 2017 mai24]. Disponible sur:http://www.encepp.eu/
12. Mcbride WG. Thalidomide and congenital abnormalities. The Lancet. 1961 16 déc;278(7216):1358.
13. Lenz W, Pfeiffer RA, Kosenow W, et al. Thalidomide and congenital abnormalities. The Lancet. 1962 janv 6;279(7219):45–46.
14. Anderka MT, Lin AE, Abuelo DN, et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen:case report and review of the literature. Am J Med Genet A. juin 2009;149A(6):1241–1248.
15. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation:a reference guide to fetal and neonatal risk. Philadelphia, Lippincott Williams & Wilkins; 2012; p. 1728.
16. Are ACE inhibitors safe in pregnancy? Lancet Lond Engl. 1989 26 août;2(8661):482–483.
17. Lindquist M. VigiBase, the WHO global icsr database system:basic Facts. Drug Inf J. 2008 sept 1;42(5):409–419.
18. Vial T, Gouraud A, Bernard N. [Terappel:description of a computerised database and examples of studies]. Therapie. févr. 2014;69(1):31–38.
19. Elefant E, Vauzelle C, Beghin D. [Centre de référence sur les agents tératogènes (CRAT):a pioneer center]. Therapie. févr. 2014;69(1):39–45.
20. Leen-Mitchell M, Martinez L, Gallegos S, et al. Mini-review:history of organized teratology information services in North America. Teratology. Avr 2000;61(4):314–317.
21. ENTIS [Internet]. [2017 mai24]. Disponible sur:https://www.entis-org.eu/
22. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy–15 years experience of ENTIS. Reprod Toxicol. 2005;20(3):331–343.
23. Weber-Schoendorfer C, Chambers C, Wacker E, Network of French Pharmacovigilance Centers, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy:a prospective multicenter cohort study. Arthritis Rheumatol Hoboken NJ. 2014 mai;66(5):1101–1110.
24. Schaefer C. Drug safety in pregnancy:utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services. Congenit Anom. Mars 2011;51(1):6–11.
25. De Graaf JP, Steegers EAP, Bonsel GJ. Inequalities in perinatal and maternal health. Curr Opin Obstet Gynecol Avr 2013;25(2):98–108.
26. Beck E, Lechner A, Schaefer C. Who seeks Teratology Information Service’s advice? Assessing the risk of selection bias in observational cohort studies on drug risks in pregnancy. Reprod Toxicol Elmsford N. janv. 2017;67:79–84.
27. Vannappagari V, Albano JD, Koram N, et al. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects:data from the Antiretroviral Pregnancy Registry. Eur J Obstet Gynecol Reprod Biol. févr. 2016;197:6–10.
28. EUROCAT [Internet]. [cité 2017 mai24]. Disponible sur:http://www.eurocat-network.eu/aboutus/whatiseurocat/whatiseurocat
29. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep Wash DC 1974. 2001;116(Suppl 1):32–40.
30. Czeizel AE, Métneki J, Béres J. 50 years of the Hungarian Congenital Abnormality Registry. Congenit Anom. févr. 2014;54(1):22–29.
31. Walley T, Mantgani A. The UK General Practice Research Database. Lancet Lond Engl. 1997 oct 11;350(9084):1097–1099.
32. Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010 févr;106(2):86–94.
33. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. Swedish personal identity number:possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–667.
34. Lacroix I, Hurault C, Sarramon MF, et al. Prescription of drugs during pregnancy:a study using EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009 avr 14;65(8):839–846.
35. Damase-Michel C, Lacroix I, Hurault-Delarue C, et al. les partenaires d’EFEMERIS. [Drug in Pregnancy:studies in the French Database EFEMERIS]. Therapie. 2014 févr;69(1):91–100.
36. Palosse-Cantaloube L, Hurault-Delarue C, Beau A-B, et al. Risk of infections during the first year of life after in utero exposure to drugs acting on immunity:a population-based cohort study. Pharmacol Res. 2016 nov;113(Pt A):557–562.
37. Beau A-B, Didier A, Hurault-Delarue C, et al. Prescription of asthma medications before and during pregnancy in France:an observational drug study using the EFEMERIS database. J Asthma off J Assoc Care Asthma. Avr 2017;54(3):258–264.
38. Montastruc F, Salvo F, Arnaud M, et al. Signal of Gastrointestinal congenital malformations with antipsychotics after minimising competition bias:a disproportionality analysis using data from vigibase(®). Drug Saf. 2016 juill;39(7):689–696.
39. Vermes G, Á M, Czeizel AE, et al. Maternal factors in the origin of isolated oesophageal atresia:a population-based case-control study. Birt Defects Res A Clin Mol Teratol. 2015 sept;103(9):804–813.
40. Beau AB, Hurault-Delarue C, Vidal S, et al. Pandemic A/H1N1 influenza vaccination during pregnancy:a comparative study using the EFEMERIS database. Vaccine. 2014 mars 5;32(11):1254–1258.
41. Beau A-B, Montastruc J-L, Lacroix I, et al. Atropinic burden of drugs during pregnancy and psychological development of children:a cohort study in the EFEMERIS database. Br J Clin Pharmacol.2016 Aug;82(2):478–486.
42. Facts |Birth Defects |NCBDDD |CDC [Internet]. [cité 2017 mai24]. Disponible sur:https://www.cdc.gov/ncbddd/birthdefects/facts.html
43. De Santis M, Straface G, Carducci B, et al. Risk of drug-induced congenital defects. Eur J Obstet Gynecol Reprod Biol. 2004 nov 10;117(1):10–19.
44. Mitchell AA, Studies of drug-induced birth defects. In:MPH BLSM, MSCE SEKM, PHARMD SH, éditeurs. Pharmacoepidemiology [Internet]. Wiley-Blackwell; 2012 [cité 24 mai 2017]. p. 487–504. Disponible sur:http://onlinelibrary.wiley.com/doi/10.1002/9781119959946.ch28/summary
45. As R. Adverse drug events:identification and attribution. Drug Intell Clin Pharm. 1987 nov;21(11):915–920.
46. Vg M, Sg M. Glucocorticoids and fetal programming part 1:outcomes. Nat Rev Endocrinol. 2014 juill;10(7):391–402.
47. Moisiadis VG, Matthews SG. Glucocorticoids and fetal programming part 2:mechanisms. Nat Rev Endocrinol. 2014 juill;10(7):403–411.
48. Charlton RA, Neville AJ, Jordan S, et al. Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf. juin. 2014;23(6):586–594.
49. De Jonge L, Garne E, Gini R, et al. Improving information on maternal medication use by linking prescription data to congenital anomaly registers:a EUROmediCAT study. Drug Saf. Nov 2015;38(11):1083–1093.
50. EUROmediCAT [Internet]. [cité 2017 juin28]. Disponible sur:http://www.euromedicat.eu/home
51. Graner S, Svensson T, A-B B, et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations:population based European register study. Bmj. 2017 févr 28;356:j629.
52. Hurault-Delarue C, Chouquet C, Savy N, et al. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women? Pharmacoepidemiol Drug Saf. Juill. 2016;25(7):770–777.
53. Hurault-Delarue C, Chouquet C, Savy N, et al. Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure:example of anxiolytics and hypnotics. Pharmacoepidemiol Drug Saf. 2017 mai;26(5):561–569.
54. Vigod SN, Gomes T, Wilton AS, et al. Antipsychotic drug use in pregnancy:high dimensional, propensity matched, population based cohort study. Bmj. 2015 mai 13;350:h2298.
55. Hernández-Díaz S, Hernán MA, Meyer K, et al. Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol. 2003 août 15;158(4):385–391.
56. Brandlistuen RE, Ystrom E, Eberhard-Gran M, et al. Behavioural effects of fetal antidepressant exposure in a Norwegian cohort of discordant siblings. Int J Epidemiol. 2015 août;44(4):1397–1407.
57. Mmhj VG, Ialm VR, Ltw DJ-VEB, et al. Teratogenic mechanisms associated with prenatal medication exposure. Therapie. 2014 févr;69(1):13–24.
58. Laurent L, Huang C, Ernest SR, et al. In utero exposure to venlafaxine, a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat. Birt Defects Res A Clin Mol Teratol. 2016 déc;106(12):1044–1055.
59. Battista M-C, Boutin M, Venne P, et al. Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. Bioanalysis. 2016 juin 28.